CD274 and neoplasm: Several biomarkers have been widely considered to be promising for predicting the immune response of gastric cancer, including PD-L1 combined positive score (CPS), microsatellite instability-high (MSI-H), tumor mutation load (TML), etc. However, according to the results of the ATTRACTION-2 study, the survival benefit of nivolumab in GC has nothing to do with the level of PD-L1 expression.